 Michelle Fullard
Concepts (100)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 18 | 2024 | 493 | 4.320 |
Why?
| | Olfaction Disorders | 4 | 2021 | 63 | 1.290 |
Why?
| | Cognitive Dysfunction | 5 | 2021 | 383 | 1.030 |
Why?
| | Deep Brain Stimulation | 2 | 2024 | 153 | 0.900 |
Why?
| | Decision Making | 1 | 2024 | 900 | 0.550 |
Why?
| | Patient Readmission | 2 | 2020 | 697 | 0.540 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 2020 | 177 | 0.530 |
Why?
| | Vitamin D Deficiency | 1 | 2017 | 186 | 0.470 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2020 | 363 | 0.450 |
Why?
| | Physical Therapy Modalities | 1 | 2017 | 308 | 0.440 |
Why?
| | Length of Stay | 1 | 2020 | 1215 | 0.430 |
Why?
| | Vitamin D | 1 | 2017 | 397 | 0.430 |
Why?
| | Patient Discharge | 1 | 2020 | 897 | 0.410 |
Why?
| | Sex Characteristics | 1 | 2017 | 762 | 0.390 |
Why?
| | Medicare | 4 | 2019 | 773 | 0.390 |
Why?
| | Healthcare Disparities | 2 | 2019 | 654 | 0.380 |
Why?
| | Patient Acceptance of Health Care | 1 | 2017 | 806 | 0.360 |
Why?
| | Aged | 15 | 2024 | 23961 | 0.330 |
Why?
| | Dementia | 2 | 2023 | 259 | 0.270 |
Why?
| | Alzheimer Disease | 2 | 2023 | 560 | 0.240 |
Why?
| | Aged, 80 and over | 6 | 2020 | 7635 | 0.240 |
Why?
| | Middle Aged | 11 | 2024 | 33479 | 0.210 |
Why?
| | Male | 15 | 2024 | 67762 | 0.200 |
Why?
| | Lewy Body Disease | 1 | 2023 | 29 | 0.190 |
Why?
| | Cannabidiol | 1 | 2024 | 119 | 0.190 |
Why?
| | Female | 14 | 2024 | 73304 | 0.180 |
Why?
| | Dronabinol | 1 | 2024 | 226 | 0.180 |
Why?
| | Humans | 19 | 2024 | 137585 | 0.170 |
Why?
| | Patient Selection | 1 | 2024 | 696 | 0.170 |
Why?
| | United States | 6 | 2024 | 14841 | 0.160 |
Why?
| | Cholinesterase Inhibitors | 1 | 2019 | 30 | 0.150 |
Why?
| | Leukoencephalopathies | 1 | 2018 | 19 | 0.150 |
Why?
| | Cholinergic Antagonists | 1 | 2019 | 30 | 0.150 |
Why?
| | Elective Surgical Procedures | 1 | 2020 | 179 | 0.150 |
Why?
| | Medication Errors | 1 | 2019 | 95 | 0.140 |
Why?
| | Cohort Studies | 3 | 2017 | 5742 | 0.140 |
Why?
| | Geography, Medical | 1 | 2017 | 11 | 0.140 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 1 | 2017 | 57 | 0.130 |
Why?
| | Databases, Factual | 2 | 2020 | 1357 | 0.130 |
Why?
| | Disease Progression | 4 | 2019 | 2757 | 0.130 |
Why?
| | Drug Prescriptions | 1 | 2019 | 245 | 0.130 |
Why?
| | White Matter | 1 | 2018 | 145 | 0.130 |
Why?
| | Proportional Hazards Models | 2 | 2019 | 1266 | 0.130 |
Why?
| | Biomarkers | 2 | 2019 | 4149 | 0.130 |
Why?
| | REM Sleep Behavior Disorder | 1 | 2016 | 14 | 0.120 |
Why?
| | Diagnosis, Differential | 2 | 2017 | 1483 | 0.120 |
Why?
| | tau Proteins | 1 | 2016 | 90 | 0.120 |
Why?
| | Neuropsychological Tests | 2 | 2018 | 1023 | 0.120 |
Why?
| | Longitudinal Studies | 3 | 2019 | 2844 | 0.110 |
Why?
| | Risk | 1 | 2017 | 912 | 0.110 |
Why?
| | Cognition Disorders | 1 | 2018 | 496 | 0.110 |
Why?
| | Salivary Ducts | 1 | 2013 | 3 | 0.110 |
Why?
| | Myelitis, Transverse | 1 | 2013 | 3 | 0.110 |
Why?
| | Carcinoma, Ductal | 1 | 2013 | 11 | 0.110 |
Why?
| | Parotid Neoplasms | 1 | 2013 | 16 | 0.110 |
Why?
| | Spinal Cord Neoplasms | 1 | 2013 | 37 | 0.100 |
Why?
| | Amyloid beta-Peptides | 1 | 2016 | 220 | 0.100 |
Why?
| | Proteomics | 1 | 2019 | 1111 | 0.100 |
Why?
| | Logistic Models | 1 | 2017 | 2074 | 0.090 |
Why?
| | Incidence | 1 | 2017 | 2804 | 0.090 |
Why?
| | Prevalence | 1 | 2017 | 2734 | 0.090 |
Why?
| | Cognition | 1 | 2018 | 1153 | 0.090 |
Why?
| | Prognosis | 1 | 2017 | 4030 | 0.070 |
Why?
| | Brain | 1 | 2018 | 2668 | 0.060 |
Why?
| | Exercise | 1 | 2018 | 2057 | 0.060 |
Why?
| | Vulnerable Populations | 1 | 2024 | 163 | 0.050 |
Why?
| | Community-Based Participatory Research | 1 | 2024 | 162 | 0.050 |
Why?
| | Minority Groups | 1 | 2024 | 266 | 0.050 |
Why?
| | Educational Status | 1 | 2024 | 470 | 0.050 |
Why?
| | Retrospective Studies | 1 | 2020 | 15657 | 0.050 |
Why?
| | Adult | 3 | 2020 | 37929 | 0.050 |
Why?
| | Smell | 1 | 2021 | 117 | 0.040 |
Why?
| | Osteopontin | 1 | 2019 | 33 | 0.040 |
Why?
| | Amidohydrolases | 1 | 2019 | 31 | 0.040 |
Why?
| | Drug Incompatibility | 1 | 2019 | 1 | 0.040 |
Why?
| | Proteoglycans | 1 | 2019 | 107 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2024 | 1993 | 0.040 |
Why?
| | Extracellular Matrix Proteins | 1 | 2019 | 153 | 0.040 |
Why?
| | Neurodegenerative Diseases | 1 | 2019 | 135 | 0.030 |
Why?
| | Social Class | 1 | 2019 | 282 | 0.030 |
Why?
| | Acute Disease | 1 | 2019 | 1007 | 0.030 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2024 | 1329 | 0.030 |
Why?
| | Internationality | 1 | 2016 | 155 | 0.030 |
Why?
| | Carrier Proteins | 1 | 2019 | 771 | 0.030 |
Why?
| | Life Style | 1 | 2018 | 490 | 0.030 |
Why?
| | Resistance Training | 1 | 2018 | 164 | 0.030 |
Why?
| | Risk Factors | 2 | 2019 | 10388 | 0.030 |
Why?
| | Comorbidity | 1 | 2019 | 1622 | 0.030 |
Why?
| | Self Report | 1 | 2018 | 827 | 0.030 |
Why?
| | Thoracic Vertebrae | 1 | 2013 | 77 | 0.030 |
Why?
| | Fatal Outcome | 1 | 2013 | 303 | 0.020 |
Why?
| | Syndrome | 1 | 2013 | 358 | 0.020 |
Why?
| | Algorithms | 1 | 2019 | 1704 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 3284 | 0.020 |
Why?
| | Radiography | 1 | 2013 | 822 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2024 | 10811 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2019 | 5472 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2016 | 5131 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3566 | 0.020 |
Why?
| | Prospective Studies | 1 | 2016 | 7604 | 0.010 |
Why?
|
|
Fullard's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|